4 results match your criteria: "Department of Medicine Johns Hopkins University Baltimore Maryland USA.[Affiliation]"
Background And Aim: Molecular-targeted agents such as lenvatinib and sorafenib have been approved to treat hepatocellular carcinoma (HCC). However, the choice between these two agents in the primary treatment for advanced HCC is still under debate with conflicting results. We sought to evaluate the efficacy of lenvatinib and sorafenib in patients with HCC.
View Article and Find Full Text PDFFrequency of acute vasodilator response (AVR) in incident and prevalent patients with pulmonary arterial hypertension: Results from the pulmonary vascular disease phenomics study.
Pulm Circ
July 2023
Division of Pulmonary and Critical Care Medicine, Department of Medicine Johns Hopkins University Baltimore Maryland USA.
The prevalence of acute vasodilator response (AVR) to inhaled nitric oxide (iNO) during right heart catheterization (RHC) is 12% in idiopathic pulmonary arterial hypertension (IPAH). AVR, however, is reportedly lower in other disease-associated pulmonary arterial hypertension (PAH), such as connective tissue disease (CTD). The prevalence of AVR in patients on PAH therapy (prevalent cases) is unknown.
View Article and Find Full Text PDFInsulin-like growth factor binding Protein-4: A novel indicator of pulmonary arterial hypertension severity and survival.
Pulm Circ
April 2023
Division of Pediatric Cardiology, Department of Pediatrics Johns Hopkins University Baltimore Maryland USA.
Article Synopsis
- A proteomic study showed that patients with pulmonary arterial hypertension (PAH) have high levels of insulin-like growth factor binding protein 4 (IGFBP4), especially in connective tissue and idiopathic PAH subtypes.
- Elevated IGFBP4 levels were significantly linked to worsening PAH severity, indicated by lower 6-minute walk distances, higher functional class, and greater right atrial pressures.
- The study identified IGFBP4 as an independent predictor of survival in PAH patients, suggesting that the dysregulation of the insulin-like growth factor axis may impact the disease's progression and severity.
Hepatoma-derived growth factor (HDGF) was previously shown to be associated with increased mortality in a small study of idiopathic and connective tissue disease-associated pulmonary arterial hypertension (PAH). In this study, we measured serum HDGF levels in a large multicenter cohort (total 2017 adult PAH-Biobank enrollees), we analyzed the associations between HDGF levels and various clinical measures using linear or logistic regression models. Higher HDGF levels were found to be significantly associated with worse pulmonary hemodynamics, prostacyclin treatment; among PAH subtypes, higher HDGF levels were most associated with portopulmonary hypertension (beta = 0.
View Article and Find Full Text PDF